Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Inclusion Criteria

• •Recurrent of refractory ependymoma or subependymoma
• •Performance Status (PS): Lansky ≥ 50% for patients ≤ 10 years of age or Karnofsky ≥ 50% for patients \>10 years of age
• •Measurable disease, defined as 1 measurable lesion that can be accurately measured in 2 planes that has not received radiation therapy within 12 weeks
• •Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
• •≥ 1 year to ≤ 21 years
• •Serum creatinine for patients ≤ 5 years in age is ≤ 0.8 mg/dL or Creatinine Clearance/Glomerular Filtration Rate (GFR) ≥ 70 mL/min/m\^2
• •Serum creatinine for patients \> 5 and ≤ 10 years in age is ≤ 1.0 mg/dL or Creatinine Clearance/GFR ≥ 70 mL/min/m\^2
• •Serum creatinine for patients \> 10 and ≤ 15 years in age is ≤ 1.2 mg/dL or Creatinine Clearance/GFR ≥ 70 mL/min/m\^2
• •Serum creatinine for patients \> 15 years in age is ≤ 1.5 mg/dL or Creatinine Clearance/GFR ≥ 70 mL/min/m\^2
• •Total bilirubin is ≤ 1.5 x upper limit of normal for age
• •Alanine aminotransferase (ALT) ≤ 3 x upper limit of normal
• •Absolute neutrophil count \> 1000/µL
• •Platelet count \> 100,000/µL
• •Hemoglobin \> 8 gm/dL
• •Neurologically stable for at least 7 days prior to randomization
• •If receiving corticosteroids, patients must be on a stable or decreasing dose for at least 7 days before randomization
• •Patients of reproductive potential must agree to proactive effective contraceptive measures for the duration of the study and for at least 90 days after completion of study drug